Literature DB >> 22156515

Identification of adenovirus serotype 5 hexon regions that interact with scavenger receptors.

Reeti Khare1, Vijay S Reddy, Glen R Nemerow, Michael A Barry.   

Abstract

Most of an intravenous dose of species C adenovirus serotype 5 (Ad5) is destroyed by liver Kupffer cells. In contrast, another species C virus, Ad6, evades these cells to mediate more efficient liver gene delivery. Given that this difference in Kupffer cell interaction is mediated by the hypervariable (HVR) loops of the virus hexon protein, we genetically modified each of the seven HVRs of Ad5 with a cysteine residue to enable conditional blocking of these sites with polyethylene glycol (PEG). We show that these modifications do not affect in vitro virus transduction. In contrast, after intravenous injection, targeted PEGylation at HVRs 1, 2, 5, and 7 increased viral liver transduction up to 20-fold. Elimination or saturation of liver Kupffer cells did not significantly affect this increase in the liver transduction. In vitro, PEGylation blocked uptake of viruses via the Kupffer cell scavenger receptor SRA-II. These data suggest that HVRs 1, 2, 5, and 7 of Ad5 may be involved in Kupffer cell recognition and subsequent destruction. These data also demonstrate that this conditional genetic-chemical mutation strategy is a useful tool for investigating the interactions of viruses with host tissues.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22156515      PMCID: PMC3302413          DOI: 10.1128/JVI.05760-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  37 in total

1.  Capsomer-specific fluorescent labeling of adenoviral vector particles allows for detailed analysis of intracellular particle trafficking and the performance of bioresponsive bonds for vector capsid modifications.

Authors:  Sigrid Espenlaub; Stéphanie Corjon; Tatjana Engler; Carolin Fella; Manfred Ogris; Ernst Wagner; Stefan Kochanek; Florian Kreppel
Journal:  Hum Gene Ther       Date:  2010-09       Impact factor: 5.695

Review 2.  Conserved domains of the class A scavenger receptors: evolution and function.

Authors:  Dawn M E Bowdish; Siamon Gordon
Journal:  Immunol Rev       Date:  2009-01       Impact factor: 12.988

3.  Characterization of species C human adenovirus serotype 6 (Ad6).

Authors:  Eric A Weaver; Mathew L Hillestad; Reeti Khare; Donna Palmer; Philip Ng; Michael A Barry
Journal:  Virology       Date:  2011-01-20       Impact factor: 3.616

4.  Atomic structure of human adenovirus by cryo-EM reveals interactions among protein networks.

Authors:  Hongrong Liu; Lei Jin; Sok Boon S Koh; Ivo Atanasov; Stan Schein; Lily Wu; Z Hong Zhou
Journal:  Science       Date:  2010-08-27       Impact factor: 47.728

5.  Crystal structure of human adenovirus at 3.5 A resolution.

Authors:  Vijay S Reddy; S Kundhavai Natchiar; Phoebe L Stewart; Glen R Nemerow
Journal:  Science       Date:  2010-08-27       Impact factor: 47.728

6.  Characterization of human adenovirus serotypes 5, 6, 11, and 35 as anticancer agents.

Authors:  Elena V Shashkova; Shannon M May; Michael A Barry
Journal:  Virology       Date:  2009-09-18       Impact factor: 3.616

7.  Scavenger receptor A: a new route for adenovirus 5.

Authors:  Hidde J Haisma; Marije Boesjes; Antoine M Beerens; Barry W A van der Strate; David T Curiel; Annette Plüddemann; Siamon Gordon; Anna Rita Bellu
Journal:  Mol Pharm       Date:  2009 Mar-Apr       Impact factor: 4.939

8.  Stability of the seven hexon hypervariable region sequences of adenovirus types 1-6 isolated in Yamagata, Japan between 1988 and 2007.

Authors:  Katsumi Mizuta; Yoko Matsuzaki; Seiji Hongo; Akira Ohmi; Michiko Okamoto; Hidekazu Nishimura; Tsutomu Itagaki; Noriko Katsushima; Hitoshi Oshitani; Akira Suzuki; Yuki Furuse; Masahiro Noda; Hirokazu Kimura; Tadayuki Ahiko
Journal:  Virus Res       Date:  2008-12-12       Impact factor: 3.303

9.  Chemical modification with high molecular weight polyethylene glycol reduces transduction of hepatocytes and increases efficacy of intravenously delivered oncolytic adenovirus.

Authors:  Konstantin Doronin; Elena V Shashkova; Shannon M May; Sean E Hofherr; Michael A Barry
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

Review 10.  Advances and future challenges in adenoviral vector pharmacology and targeting.

Authors:  Reeti Khare; Christopher Y Chen; Eric A Weaver; Michael A Barry
Journal:  Curr Gene Ther       Date:  2011-08       Impact factor: 4.391

View more
  34 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

2.  Conformational changes in the adenovirus hexon subunit responsible for regulating cytoplasmic dynein recruitment.

Authors:  Julian Scherer; Richard B Vallee
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

Review 3.  Gene therapy with helper-dependent adenoviral vectors: lessons from studies in large animal models.

Authors:  Nicola Brunetti-Pierri; Philip Ng
Journal:  Virus Genes       Date:  2017-06-07       Impact factor: 2.332

4.  Combined Genetic and Chemical Capsid Modifications of Adenovirus-Based Gene Transfer Vectors for Shielding and Targeting.

Authors:  Franziska Jönsson; Claudia Hagedorn; Florian Kreppel
Journal:  J Vis Exp       Date:  2018-10-26       Impact factor: 1.355

5.  Coagulation factor defends adenovirus from immune attack.

Authors:  Glen R Nemerow
Journal:  Nat Med       Date:  2013-04       Impact factor: 53.440

Review 6.  Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.

Authors:  Franziska Jönsson; Florian Kreppel
Journal:  Virus Genes       Date:  2017-07-28       Impact factor: 2.332

7.  Circulating antibodies and macrophages as modulators of adenovirus pharmacology.

Authors:  Reeti Khare; Matthew L Hillestad; Zhili Xu; Andrew P Byrnes; Michael A Barry
Journal:  J Virol       Date:  2013-01-16       Impact factor: 5.103

8.  Coagulation factor X shields adenovirus type 5 from attack by natural antibodies and complement.

Authors:  Zhili Xu; Qi Qiu; Jie Tian; Jeffrey S Smith; Gina M Conenello; Takashi Morita; Andrew P Byrnes
Journal:  Nat Med       Date:  2013-03-24       Impact factor: 53.440

9.  Human full-length coagulation factor X and a GLA domain-derived 40-mer polypeptide bind to different regions of the adenovirus serotype 5 hexon capsomer.

Authors:  Sudir Sumarheni; Saw See Hong; Véronique Josserand; Jean-Luc Coll; Pierre Boulanger; Guy Schoehn; Pascal Fender
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

Review 10.  Innate immunity to adenovirus.

Authors:  Rodinde Hendrickx; Nicole Stichling; Jorien Koelen; Lukasz Kuryk; Agnieszka Lipiec; Urs F Greber
Journal:  Hum Gene Ther       Date:  2014-04-08       Impact factor: 5.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.